Actively Recruiting
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
Led by St Vincent's Hospital, Sydney · Updated on 2026-04-27
24
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
S
St Vincent's Hospital, Sydney
Lead Sponsor
U
University of Technology, Sydney
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
CONDITIONS
Official Title
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men with high-risk biochemical recurrence of prostate cancer without experience of androgen deprivation therapy (ADT) or androgen receptor pathway inhibitor (ARPI).
- Men with ADT and/or ARPI experience who have experienced breast-related side effects from this treatment.
You will not qualify if you...
- Men receiving psychiatric care as a result of their prostate cancer diagnosis or treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kinghorn Cancer Centre
Sydney, New South Wales, Australia, 2010
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here